X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMP321 (eftilagimod alpha), a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity. It is being evaluated in phase 2 clinial trials for first line treatment of metastatic non-small cell lung cancer & head & neck squamous cell cancer.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: Efti
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
IMP321 (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with paclitaxel under phase 2/3 clinical trials forthe treatment of patients with metastatic breast carcinoma.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Efti (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with Bavencio (avelumab) under phase 1 clinical trials forthe treatment of patients with metastatic urothelial carcinoma.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
IMP321 (eftilagimod alpha), a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity. It is being evaluated in phase 2 clinial trials for first line treatment of metastatic non-small cell lung cancer & head & neck squamous cell cancer.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer. It is being investigated in combination with MSD’s anti-PD-1 therapy pembrolizumab as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
IMP321 (eftilagimod alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in combination with KEYTRUDA for NSCLC.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase III trial in non-small cell lung cancer.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in combination with KEYTRUDA for soft tissue sarcoma.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
Under the agreement, Charles River will conduct a GLP toxicology study for IMP761, a first-in-class LAG-3 agonist antibody and Immutep's proprietary preclinical candidate for autoimmune diseases.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Charles River Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 29, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in soft tissue sarcoma in neoadjuvant setting.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
